

Ticket #:	Request Date:	Request Time:
	•	•

PHYSICIAN CERTIFICATION PRIOR AUTHORIZATION FORM

A request for the patient identified below has been made for the dispensing of **Orfadin®** nitisnone. Based on recent clinical information, we require more information before this prescription can be paid by the patient's health benefit plan. Please fill out the following information and return to us as indicated below:

A. Member Information Patient Name:	Plan Name	/Plan ID·									
r auent maine.			Tian Name/Call ID.								
Patient ID:			Patient Date of Birth:			Pat	Patient Contact Phone #:				
B. Physician Information											
			n Address:								
Physician DEA #:	Physician Phone #:				Physician Fax #:						
Drug Name and Strength:	Direction (SIG):				QTY and Days Supply:				NDC #:		
C. Pharmacy Information											
Pharmacy Name:	NABP#:			Pharmacy	Pharmacy Phone #:			Pharma	icy Fax #:		
D. Clinical Information (Please fill	out the followi	ving informati	on: circle a	ll that appl	y)						
Is the patient's diagnosis hereditary tyrosinemia type I?								YES	NO		
Are the dietary restrictions of tyrosine and phenylalanine alone sufficient to maintain the urinary succinylacetone at or below detectable levels?							YES	NO			
Is the patient currently placed on a liver transplantation waiting list?							YES	NO			
4. In your opinion, will this patient likely become a candidate for liver transplantation within the next year?							YES	NO			
5. The patient's current weight isKg											
Authorized Medical Signature:											
Telephone:						Date:					

When Completed Return To:

MC-Rx Clinical Division, 1267 Professional Parkway, Gainesville, GA 30507 1-866-965-Drug (3784) / Fax # 866-999-7736

^{**}Please note that this form is to be completed by the prescribing physician. This form and its contents are permissible under HIPAA as the protected health information (PHI) contained in this letter is only being used for purposes related to the provision of treatment, payment and healthcare operations (TPO). HIPAA does restrict the communication of PHI with providers for TPO related purposes.